Middle East and Africa Multiple Sclerosis Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Nov 2020
  • MEA
  • 350 Pages
  • No of Tables: 193
  • No of Figures: 46

Middle East and Africa Multiple Sclerosis Treatment Market, By Disease Type (Relapsing–Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing–Remitting Multiple Sclerosis (RES)), Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), Drug Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospital, Homecare, Specialty Centers, Others), Distribution Channel (Retail Sales, Direct Tender), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa)- Industry Trends and Forecast to 2027

Middle East and Africa Multiple SclerosisMarket Analysis and Insights : Middle East and Africa Multiple Sclerosis Treatment Market

Multiple sclerosis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.5% in the forecast period of 2020 to 2027 and is expected to reach USD 315.64 million by 2027. Increasing need for better multiple sclerosis treatment options, rising government initiatives are the major drivers which propelled the demand of the market in the forecast period.

Multiple sclerosis is a type of autoimmune, chronic, inflammatory disease which affects the central nervous system, specifically brain and other tissues of the body. Multiple sclerosis is a type of demyelinating disease in which insulating damaged of nerve cells in the brain as well as spinal cord. In multiple sclerosis the treatment focuses on fast recovery, slowing the progression of the disease and reduces the symptoms of multiple sclerosis. The symptoms of multiple sclerosis are depends on the amount of damage to the nerves and the form and position of affected nerves. The multiple sclerosis causes various types of symptoms, including vision loss, pain, fatigue and impaired coordination. This duration of disease, symptoms and severity are varying from person to person

Multiple sclerosis treatment demand has increased as compared to the precise year with increasing prevalence of multiple sclerosis along with the increasing need for better multiple sclerosis treatment options and rising government initiatives. Further, high cost of treatment and panels is expected to restraint the demand of multiple sclerosis treatment and expected to slow down the growth of the multiple sclerosis treatment market in the forecasted period.

The multiple sclerosis treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Multiple SclerosisMiddle East and Africa Multiple Sclerosis Treatment Market Scope and Market Size

The multiple sclerosis treatment market is segmented on the basis of disease type, treatment, drug type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the multiple sclerosis treatment market is segmented into relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS) and severe relapsing–remitting multiple sclerosis (RES). In 2020, relapsing–remitting multiple sclerosis (RRMS) segment is dominating the multiple sclerosis treatment market because it is the most common form of multiple sclerosis at onset and accounts for about 85% of all cases.
  • On the basis of treatment, the multiple sclerosis treatment market is segmented into symptomatic therapies, abortive therapies/treatment of acute exacerbations and preventive therapies. In 2020, preventive therapies segment is dominating the multiple sclerosis treatment market as the immune system eats away at the protective covering of nerves, and the prevention is highly sought after.
  • On the basis of drug type, the multiple sclerosis treatment market is segmented into branded and generic. In 2020, branded segment is dominating the multiple sclerosis treatment market because of large number of products which are being launched from time-to-time by several companies making it difficult for generics to take over the market.
  • On the basis of route of administration, the multiple sclerosis treatment market is segmented into oral and parenteral. In 2020, oral segment is dominating the multiple sclerosis treatment market because of the increased bioavailability of the oral drug at the target site.
  • On the basis of end user, the multiple sclerosis treatment market is segmented into hospital, specialty centers, homecare and others. In 2020, hospital segment is dominating the multiple sclerosis treatment market because of the large number of patients visiting the hospitals due to the presence of skilled professionals and advanced technology for the diagnosis.
  • On the basis of distribution channel, the multiple sclerosis treatment market is segmented into direct tender and retail sales. In 2020, retail sales segment is dominating the multiple sclerosis treatment market because retail sales focus heavily on the costs associated with overhead and they provide instant gratification.

Middle East and Africa Multiple Sclerosis Treatment Market Country Level Analysis

Middle East and Africa multiple sclerosis treatment market is analysed and market size information is provided by country, disease type, treatment, drug type, route of administration, end user and distribution channel as referenced above.

The countries covered in the Middle East and Africa multiple sclerosis treatment market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.

South Africa is expected to grow with the substantial growth rate in the forecast period of 2020 to 2027 in Middle East and Africa region due to increasing the awareness for multiple sclerosis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Multiple Sclerosis Treatment Market

Multiple sclerosis treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with multiple sclerosis treatment sales, impact of advancement in the multiple sclerosis treatment and changes in regulatory scenarios with their support for the multiple sclerosis treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Multiple Sclerosis Treatment Market Share Analysis

Multiple sclerosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to multiple sclerosis treatment market.

The major players covered in the report Genzyme Corporation (A subsidiary of Sanofi), Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), F. Hoffmann-La Roche Ltd, Merck KGaA, Mallinckrodt, Pfizer Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Novartis AG, CELGENE CORPORATION (a subsidiary of Bristol-Myers Squibb Company), Bayer AG and other Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the multiple sclerosis treatment market.

For instance,

  • In August 2020, Mylan N.V. launched the generic drug Dimethyl fumarate delayed release capsules 120 mg and 240 mg for the treatment of relapsing forms of multiple sclerosis (MS). The newly launched drug is therapeutically equivalent to the Biogen's Tecfidera capsules. This new FDA approved drug launched by the company during the COVID-19 pandemic has increased its credibility in the market
  • In June 2020, Bristol-Myers Squibb Company, a parent company of CELGENE CORPORATION announced that they have launched their new oral drug for a relapsing form of multiple sclerosis (MS) named ZEPOSIA (ozanimod). This new product launched by the company will increase its demand in the market in the future

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the multiple sclerosis treatment market which also provides the benefit for organisation to improve their offering for multiple sclerosis treatment.

Customization Available : Middle East and Africa Multiple Sclerosis Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE

TABLE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 1 MIDDLE EAST AND AFRICA RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 62 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 63 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 79 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 81 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 82 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 83 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 84 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 85 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 86 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 99 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 100 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 103 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 104 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 105 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 106 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 109 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 110 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 111 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 112 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 113 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 114 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 121 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 122 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 125 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 126 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 127 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 128 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 137 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 138 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 139 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 140 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 141 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 142 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 144 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 146 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 149 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 150 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 165 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 166 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 167 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 168 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 169 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 170 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 171 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 172 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 173 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 187 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 188 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 189 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 190 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 191 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 192 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 193 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions